每年7月8日世界过敏性疾病日，旨在唤起全球对过敏问题的重视。职业环境中的粉尘、化学因子等致敏 原已经成为了劳动者健康的隐形挑战，以"渝承守护 西续力量"为核心理念的第109届中国国际劳动保护 用品交易会，汇聚从头到脚的个体防护装备创新成果，为职业健康防护领域搭建集技术展示、行业对 话、产业升级于一体的专业平台，为制造业、医疗、农业、能源等领域的劳动者构筑起科技赋能的健康 防线。 世界过敏性疾病日聚焦于全球日益严峻的过敏健康威胁，而职业环境中的过敏风险与职业健康安全问题 紧密相关。在化工工业、纺织、食品加工等行业，从业者长期暴露于化学试剂、粉尘、生物过敏原等有 害物中，易引发呼吸道过敏、接触性皮炎等病症，不仅损害个人健康，更可能影响工作效率与生活质 量。个体防护装备(PPE)作为职业健康安全的最后一道防线，在预防职业性过敏方面发挥关键作用。通 过科学选择、正确使用个体防护装备，结合良好的通风系统与工作流程优化，可显著降低职业环境中的 过敏风险，推动职业健康安全体系的完善，助力实现劳动者的健康福祉与企业可持续发展的双赢目标。 防护经纬：科技织就安全网 在劳保会现场，您将看到丰富多元的展品构建起的职业防护立体网络。 ...

常见的皮肤相关的过敏性疾病包括荨麻疹、湿疹、特应性皮炎等。李珺莹介绍，荨麻疹是临床中较 为常见的一种变态反应性皮肤疾病，主要临床特点为边缘清楚，大小不一的瘙痒性风团。大部分皮疹， 多则一天左右，少则几分钟或几小时，便可自行消退，消退后不留任何痕迹，但病情严重者会出现喉头 水肿，甚至窒息。 专家介绍，湿疹是由多种内外因素引起的瘙痒剧烈的一种皮肤炎症反应，属于一种过敏刺激因素引 发的疾病。患者的过敏体质是本病的重要因素，与遗传有关，可随年龄的增长、环境改变而改变，过度 忧虑、紧张、情绪激动、失眠、劳累等都可能诱发或加重病情。 特应性皮炎是一种与遗传过敏体质有关的慢性、复发性、炎症性皮肤病，患者常伴有过敏性鼻炎、 哮喘、过敏性结膜炎或食物过敏等其他过敏性疾病。 新华社天津7月8日电（记者张建新、栗雅婷）今年7月8日是第21个"世界过敏性疾病日"。夏日炎 炎，高温高湿的天气为过敏性疾病发作"推波助澜"，尤其是过敏性皮肤病患者往往更易"中招"。专家提 醒，患者应明确并远离过敏原，清淡饮食、规律作息，调节自身免疫力。 过敏，即变态反应、超敏反应，指异常的、过高的免疫应答。天津市中医药研究院附属医院皮肤科 主任医师李珺莹表 ...

"喝有水垢的水易得肾结石""频繁洗头致脱发""伤口须用酒精消毒"，这些说法是真的吗？日前，国家卫生健康委针对多个常见的健康误区，进行了有针对性 的科普。 喝有水垢的水容易得肾结石？ 有一种常见的说法："喝有水垢的水容易得肾结石"，这是真的吗？ 专家介绍"喝有水垢的水易得肾结石"这样的说法是一个误区。水垢，是水里的钙离子、镁离子与碳酸氢盐在加热过程中反应生成的碳酸钙和氢氧化镁沉淀。 水中的矿物质含量越高，水的硬度越大，也就是所说的"硬水"。国际上通常用碳酸钙的含量来衡量水的硬度，单位是毫克每升（mg/L），当水的硬度高于 200mg/L时，烧水时易产生水垢。水垢进入人体后，部分可被分解，未被分解的成分也能通过代谢排出体外。 北京大学第一医院泌尿外科主治医师 陈宇珂：对于健康人群，饮用硬水并不会直接导致肾结石。若饮水量不足，尿液浓缩，反而会增加泌尿系统结石的风 险。 据介绍，对于正常人来说，头发的脱落主要是由于毛囊进入休止期后的自然脱落，而不是因为频繁洗头。病理状态下的脱发可能关系到免疫、遗传、激素水 平、精神应激、营养状态和某些药物的副作用等。与这些因素相比，洗头的影响微乎其微。适度洗头可以清除头皮上的过多皮脂 ...

炎炎夏日，让人难受的不只是高温酷暑，还有不少与之相关的过敏性疾病。在世界过敏性疾病日到 来之际，科技日报记者走访多位医院专家，让他们为解决夏日的敏感烦恼支招。 鲁建云介绍，常见的日光性皮炎患者皮疹通常位于暴露部位，如面、颈、手背等。在曝晒后数小时 至数天内，患者皮肤开始出现边界清晰的红斑，严重者可发展为水疱、大疱，伴灼痛、瘙痒或刺痛感。 红斑通常在24—48小时达到高峰，随后逐渐脱屑、色素沉着。 "日光性皮炎不仅影响生活质量，长期反复发病还可能增加皮肤癌风险。通过科学防晒和及时干 预，人们可有效降低紫外线对皮肤的损伤。"中南大学湘雅医院皮肤科主任粟娟说。 一是可以采用物理防护。专家建议，白天出行选择使用紫外线防护系数大于50的防晒衣、防晒伞、 宽边帽和太阳镜。二是可以采用化学防护。专家建议日常可选择涂抹紫外线防护系数30以上、PA+++以 上的防晒霜，并在出门前15—30分钟涂抹，确保防晒霜有足够时间成膜。此外，建议每2小时补涂一 次，特别是在出汗或游泳后。三是要做好生活调整。专家建议易感人群减少光敏性食物，如芹菜、香 菜、木耳等的摄入；对光敏性药物敏感者，则需咨询医生调整用药方案。 "特别要提醒的是，即便阴 ...

Group 1 - The article highlights that summer is also a peak season for allergies, contrary to the common belief that spring is the highest season for allergies [1] - It discusses the concept of photosensitivity, where certain foods and medications can exacerbate UV allergies, particularly in individuals with fair skin and a family history of such allergies [2][3] - Key preventive measures against UV allergies include avoiding sun exposure during peak hours, using broad-spectrum sunscreen, and checking medication labels for photosensitivity warnings [4] Group 2 - The article emphasizes the rise of mold allergies during the rainy season, particularly affecting children, who may be misdiagnosed with colds [5] - It notes that mold thrives in humidity levels of 60%-80%, which can significantly increase during the rainy season, leading to higher concentrations in home environments [5] - The article clarifies misconceptions about allergies, stating that they are not a sign of low immunity but rather an overreaction to harmless substances [6] Group 3 - It mentions that while some children may experience a reduction in allergy symptoms as they age, this does not guarantee complete resolution of allergies [7] - The progression of allergies in children is described as a "four-part series," starting from eczema in infancy to asthma in adolescence [8] - Early intervention is crucial, as untreated allergies in children can worsen or affect other organs [9] Group 4 - The article warns that severe allergic reactions can be life-threatening, primarily caused by food and drug allergies, which can develop rapidly [11] - It discusses the importance of maintaining appropriate temperature and humidity levels to prevent allergies, noting that extremes in either can trigger allergic reactions [12]

At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which took place in Glasgow, Scotland, from 13 to 16 June 2025, the Danish pharmaceutical company ALK presented extensive data on anaphylaxis and paediatric allergy. During the EAACI 2025 scientific programme, ALK sponsored two major symposia and participated at several oral sessions, presenting data on the latest innovation in anaphylaxis, children with respiratory allergy, and recent advances in peanut food allergy. ...

RAPT Therapeutics (RAPT) FY 2025 Conference June 10, 2025 09:20 AM ET Speaker0 All right. Good morning, everyone. Thanks for joining us here at the Goldman Sachs Annual Healthcare Conference. Thrilled to be joined today by the team from RAP Therapeutics. Maybe I'll let you guys introduce yourself and then we can dive into the business. Speaker1 Great. So of all, thanks Corinne for the invitation. Really appreciate it. I'm excited to be here. My name is Brian Wong. I'm the CEO and President of Wrap Therapeut ...

据 IPO 早知道消息， 天辰生物医药（苏州）有限公司（下称 " 天辰生物 " ） 日前 完成超 2 亿元 C 轮融资。本轮融资由 弘晖基金 、原有股东 启明创投 共同领投， 临创蓝湾基金 、 贝达基金 、 真脉基金 跟投，原有股东 三奕资本 、 山证创新 等持续加码。 近一年内，天辰生物完成 了 B2 、 B3 及 C 轮融资，累计融资金额超 3 亿元 。本轮 融资将重点 用于核心管线 ，即 新一代抗 IgE 抗体 LP-003 的 III 期临床和后续的商业化准备，以及全球首创 补体双功能抗体 LP-005 的多个适应症的 II 期临床开发，进一步巩固天辰生物在过敏与补体疾病领 域的创新优势。 LP-003 作为全球进展最快的在研抗 IgE 抗体， LP-003 已进入过敏性鼻炎的 III 期临床，预计 2026 年初提交产品上市申请（ NDA/BLA ）；第二个适应症慢性荨麻疹的 III 期临床也将于 2026 年启动； 此外， 过敏性哮喘、食物过敏等适应症的 II 期临床也在推进中， 公司 将持续拓展产品的 商业化价值。 全球进展最快的在研抗IgE抗体LP-003商业化进程提速。 本文为IPO早知道原 ...

Core Insights - Zhejiang Iwu Biological Technology Co., Ltd. has made significant progress in the field of allergic disease diagnostics with the approval of its "Dermatitis Diagnostic Patch 02" for clinical trials by the National Medical Products Administration [1][5] Group 1: Product Development - The "Dermatitis Diagnostic Patch 02" focuses on diagnosing three common allergens: Kathon, p-phenylenediamine, and formaldehyde, which are frequently encountered in daily life and are known to cause allergic contact dermatitis [4][6] - The clinical trial process will follow a rigorous drug development protocol, including Phase I, II, and III trials to assess safety, efficacy, and dosage [5][6] Group 2: Market Position and Impact - Iwu Biological is a leading domestic pharmaceutical company specializing in the research and innovation of allergic disease diagnostics and treatments, with a strong R&D team and a history of successful product launches [6][7] - The approval of the "Dermatitis Diagnostic Patch 02" is expected to enhance the company's competitiveness in the diagnostic market and contribute to the development of the allergic disease diagnostics sector in China [6][7]

ARS Pharmaceuticals (SPRY) Q1 2025 Earnings Call May 14, 2025 08:30 AM ET Company Participants Justin Chakma - Chief Business OfficerRichard Lowenthal - Co Founder, President, CEO & DirectorEric Karas - Chief Commercial OfficerKathleen Scott - Chief Financial OfficerRyan Deschner - Vice President - Equity ResearchJosh Schimmer - Managing DirectorLouise Chen - Managing Director Conference Call Participants Roanna Ruiz - Senior Managing Director, Biotechnology AnalystLachlan Hanbury-Brown - Biotech Equity Res ...